Gilead Sciences

Courtesy of Gilead Sciences
  • Previous Rank
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Assets ($M)
  • Employees

Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.

Company Information

CEOJohn F. Milligan
SectorHealth Care
HQ LocationFoster City, CA
Years on Global 500 List3

Key Financials (Last Fiscal Year)

Revenues ($M)$30,390
Profits ($M)$13,501
Assets ($M)$56,977
Total Stockholder Equity ($M)$18,887

Profit Ratios

Profit as % of Revenues44.4%
Profits as % of Assets23.7%
Profits as % of Stockholder Equity71.5%